Skip to main content
Clinical Trials/EUCTR2009-011603-23-IT
EUCTR2009-011603-23-IT
Active, not recruiting
Not Applicable

Evaluation of Haemostatic Efficacy, Tolerability and Safety of Kedrion Fibrin Sealant in patients undergoing major or minor Liver Surgery. Multicenter, Controlled, Open Label Randomised Phase II/III study. - KB048

KEDRIO0 sitesJune 30, 2009

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
KEDRIO
Status
Active, not recruiting
Last Updated
14 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 30, 2009
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
KEDRIO

Eligibility Criteria

Inclusion Criteria

  • 1\.Age \> 18 years
  • 2\.Anatomical and non\-anatomical resections, whose section is \> 20 cm2
  • 3\.The subjects or their authorized legal representatives must have received adequate information regarding the nature of the trial, agree on study purposes, and have signed an informed consent form approved by the Ethical Committee.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • 1\.Anatomical and non\-anatomical resections, whose section is \< 20 cm2
  • 2\.Use of haemostatic agents apart from those foreseen by the study protocol
  • 3\.History of congenital coagulation disorders
  • 4\. Presence of any conditions which, in the investigator?s judgment, may interfere with study objective evaluation or with the patient?s participation in the study.
  • 5\.Previous exposure to products containing aprotinine of bovine origin
  • 6\.The patient refused to sign the written informed consent required for participation, or participated in another clinical study during the month prior to study start date (the subject received other study drugs during the last 30 days).
  • 7\.Known allergies to hemoderivatives and/or to haemocomponents.

Outcomes

Primary Outcomes

Not specified

Similar Trials